Live feed
Filing
SCHEDULE 13D/A
SCHEDULE 13D/A0000929638-26-000184·CASI Pharmaceuticals, Inc.
Schedule 13D ownership disclosure
CASI PHARMACEUTICALS INC
Ordinary Shares, par value US$0.0001 per share · CUSIP: G1933S101
Event date: 2025-09-30
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- SPARKLE BYTE LTDReported CIK 0001663831
Shares: 1,019,852 · Class: 5%
- SNOW MOON LTDReported CIK 0001663833
Shares: 1,019,852 · Class: 5%
- TIANJIN JINGRAN MANAGEMENT CENTER (LIMITED PARTNERSHIP)Reported CIK 0001664019
Shares: 1,019,852 · Class: 5%
- Beijing Hexie Kangjian Investment Center (Limited Partnership)
Shares: 1,019,852 · Class: 5%
- Beijing Hexie Tiancheng Investment Management Center (Limited Partnership)
Shares: 1,019,852 · Class: 5%
- He Xie Ai Qi Investment Management (Beijing) Co., Ltd.
Shares: 1,019,852 · Class: 5%
- Xizang Hexie Enterprise Management Co., Ltd.
Shares: 1,019,851 · Class: 5%
- Zhuhai Hexie Zhiyuan Management Consulting Co., Ltd.
Shares: 1,019,852 · Class: 5%
- Jianguang Li
Shares: 1,019,852 · Class: 5%
- Dongliang Lin
Shares: 1,019,852 · Class: 5%
- Jingbo Wang
Shares: 1,019,852 · Class: 5%
- Kuiguang Niu
Shares: 1,019,852 · Class: 5%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000929638-26-000184
- Form type
- SCHEDULE 13D/A
- Filer
- CASI Pharmaceuticals, Inc.
- CIK
- CIK 1962738
- Filed
- Jan 20, 2026
- Reporting period
- Sep 30, 2025
- Description
- Schedule 13D beneficial ownership